J&J hormone-blocking pill slows prostate cancer spread

CHICAGO (Reuters) – A trial of Johnson & Johnson’s Zytiga in certain prostate cancer patients showed that it doubled the amount of time they lived without the disease getting worse, potentially offering new hope for patients who see their cancer return. The trial, involving 1,088 patients who had stopped responding to traditional hormonal drugs but had not been treated with chemotherapy, found that Zytiga slowed the spread of the disease by 58 percent. …